This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (538) Cancer and Clinical Trials (19)

Published on in Vol 7, No 7 (2018): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/11191, first published .
Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Enzalutamide Versus Abiraterone as a First-Line Endocrine Therapy for Castration-Resistant Prostate Cancer: Protocol for a Multicenter Randomized Phase 3 Trial

Authors of this article:

Isao Hara1 Author Orcid Image ;   Shimpei Yamashita1 Author Orcid Image ;   Satoshi Nishizawa1 Author Orcid Image ;   Kazuro Kikkawa1 Author Orcid Image ;   Toshio Shimokawa2 Author Orcid Image ;   Yasuo Kohjimoto1 Author Orcid Image
Article Authors Cited by (7) Tweetations (1) Metrics

Isao Hara   1 , MD, PhD ;   Shimpei Yamashita   1 , MD ;   Satoshi Nishizawa   1 , MD, Ph D ;   Kazuro Kikkawa   1 , MD, PhD ;   Toshio Shimokawa   2 , PhD ;   Yasuo Kohjimoto   1 , MD, PhD

1 Department of Urology, Wakayama Medical University, Wakayama, Japan

2 Clinical Research Center, Wakayama Medical University, Wakayama, Japan

Corresponding Author: